DMK Pharmaceuticals Corporation (DMKPQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 23, 2025, 8:00 PM EDT
Market Cap10.00
Revenue (ttm)3.62M
Net Income (ttm)-22.41M
Shares Out10.09M
EPS (ttm)-6.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,711
Average Volume1,475
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Rangen/a
Beta28.87
RSI12.78
Earnings DateMar 14, 2025

About DMK Pharmaceuticals

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other aller... [Read more]

Sector Healthcare
Employees 12
Stock Exchange OTCMKTS
Ticker Symbol DMKPQ
Full Company Profile

Financial Performance

In 2022, DMK Pharmaceuticals's revenue was $4.76 million, an increase of 115.34% compared to the previous year's $2.21 million. Losses were -$26.48 million, -42.22% less than in 2021.

Financial Statements

News

There is no news available yet.